2P-0585 Rosuvastatin improves apolipoproteins A-1 and B more than atorvastatin, simvastatin, and pravastatin (STELLAR trial results)

Stein, Evan A.; Jones, P.; Rhyne, James M.; Caplan, Richard; Gold, Alex; Blasetto, James W.

doi:10.1016/s1567-5688(03)90724-0

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6,8] All agents increased plasma HDL-C levels in recipients intent-to-treat analyses (table V). [6] For mean atorvastatin 10 mg/day recipients, significantly more rosuvastatin plasma Apo A1 levels, significant (all p < 0.002) increases were 10 mg/day recipients achieved their target of <100 mg/dL (60% vs reported with rosuvastatin 10 mg/day (8.2% increase) versus 19% in the atorvastatin group; p < 0.05), although response rates atorvastatin 40 mg/day (3.5%) and pravastatin 10 mg/day (3.5%), [7] Plasma Apo B levels were tin 20 mg/day [59,62] or simvastatin 20 mg/day [59,62] (table V).…”

Section: Dose-finding Trialsmentioning

confidence: 97%

“…There were generally no between-group differences in correlation (p < 0.001 in both trials). [6,8] All agents increased plasma HDL-C levels in recipients intent-to-treat analyses (table V). [58] was reduced by 36-54% in rosuvastatin 5-40 mg/day recipients Results from the 6-week, randomized, nonblind, multicenter versus 2.1% in the placebo group (all p < 0.001).…”

Section: Dose-finding Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Rosuvastatin

Scott¹,

Curran²,

Figgitt³

2004

American Journal of Cardiovascular Drugs

View full text Add to dashboard Cite

Rosuvastatin (Crestor), an HMG-CoA reductase inhibitor (statin), has a favorable pharmacologic profile, including its selective uptake by hepatic cells, hydrophilic nature, and lack of metabolism by cytochrome p450 (CYP) 3A4 isoenzyme. This last property means that the potential for CYP3A4-mediated drug interactions and, as a consequence, adverse events is low in those requiring concomitant therapy with a statin and agents metabolized by CYP3A4. In a broad spectrum of adult patients with dyslipidemias, oral rosuvastatin 5-40 mg once daily effectively and rapidly improved lipid profiles in several large, randomized, mainly double-blind, multicenter trials of up to 52 weeks' duration. After 12 weeks' treatment, rosuvastatin was significantly (all p < 0.05) more effective at milligram equivalent dosages than atorvastatin, pravastatin, and simvastatin in improving the overall lipid profiles of patients with hypercholesterolemia (intent-to-treat analyses). Moreover, overall a significantly (all p < 0.001) higher proportion of patients achieved National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III low-density lipoprotein-cholesterol (LDL-C) goals with rosuvastatin 10 mg/day than with therapeutic starting dosages of these other statins after 12 weeks' treatment in pooled analyses. Rosuvastatin treatment for up to 52 weeks was generally well tolerated in patients with dyslipidemias in clinical trials. The most commonly reported treatment-related adverse events were myalgia, constipation, asthenia, abdominal pain, and nausea; these were mostly transient and mild. The incidence of proteinuria or microscopic hematuria with rosuvastatin 10 or 20 mg/day was <1% versus <1.5% with rosuvastatin 40 mg/day; these events were mostly transient and not associated with acute or progressive deterioration in renal function at recommended dosages. Importantly, very few patients experienced elevations in serum creatine phosphokinase (CPK) levels of over [corrected] 10-fold the upper limit of normal (0.2-0.4% of patients) or treatment-related myopathy (

show abstract

Section: Dose-finding Trialsmentioning

confidence: 97%

Section: Dose-finding Trialsmentioning

confidence: 99%